Anacor Pharmaceuticals Inc. Sets New 1-Year High at $17.98 (ANAC)
Anacor Pharmaceuticals (NASDAQ:ANAC) set a new 52-week high during trading on Friday, Stock Ratings Network reports. The stock traded as high as $17.98 and last traded at $17.92, with a volume of 327,261 shares. The stock had previously closed at $16.98.
A number of research firms have recently commented on ANAC. Analysts at Canaccord Genuity raised their price target on shares of Anacor Pharmaceuticals from $17.00 to $24.00 in a research note to investors on Tuesday, October 29th. They now have a “buy” rating on the stock. Finally, analysts at Wedbush raised their price target on shares of Anacor Pharmaceuticals from $20.00 to $29.00 in a research note to investors on Friday, October 18th.
In other Anacor Pharmaceuticals news, CEO David Perry sold 65,000 shares of Anacor Pharmaceuticals stock in a transaction that occurred on Thursday, January 9th. The stock was sold at an average price of $16.32, for a total transaction of $1,060,800.00. Following the transaction, the chief executive officer now directly owns 441,306 shares of the company’s stock, valued at approximately $7,202,114. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Anacor Pharmaceuticals (NASDAQ:ANAC) last announced its earnings results on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.39) by $0.02. The company had revenue of $3.60 million for the quarter, compared to the consensus estimate of $2.57 million. During the same quarter last year, the company posted ($0.46) earnings per share. Anacor Pharmaceuticals’s revenue was up 45.7% compared to the same quarter last year.
Anacor Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.